Scholarlink

Abstract <p>Objective. Based on our preliminary research, our team further assessed the application value of <i>PPIH</i> in the early diagnosis and prognosis monitoring of hepatocellular carcinoma (HCC), establishing a solid foundation for elucidating the primary molecular mechanisms of <i>PPIH</i> in the onset and progression of HCC. We utilized bioinformatics analysis combined with clinical sample evaluation to study <i>PPIH</i>’s mRNA and protein expression and its gene regulation networks in HCC. Additionally, we used data from the TCGA database to examine the relationship between <i>PPIH</i> expression and HCC patient age, gender, and TP53 gene mutation status. The mRNA expression level of <i>PPIH</i> in HCC patients was higher than that in adjacent normal tissues, and Western Blot analysis preliminarily confirmed that PPIH expression was also elevated in HCC tissues compared to matched adjacent normal tissues. However, compared to the normal human liver cell line (L-02), the expression of PPIH in liver cancer cell lines (SMCC7721, HepG2, HepG2.2.15, and MHCC97H) showed no significant differences. Furthermore, the <i>PPIH</i> gene is associated with the regulation of non-coding RNA. It was also found that <i>PPIH</i> expression is positively correlated with the TP53 mutation burden in HCC. However, regardless of the TP53 gene mutation status in HCC, there is no correlation between <i>PPIH</i> expression levels and the gender or age of HCC patients. <i>PPIH</i> holds significant reference value for the diagnosis and prognosis monitoring of HCC and shows potential for clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Application Value of High PPIH Expression in Hepatocellular Carcinoma

  • 期刊论文

  • 发表日期：

    2025年2月1日

查看全文
  • Renjie Wang,
  • Haini Chen,
  • Sha Xiang,
  • Yun Hu,
  • Shengrong Pan,
  • Jun Ye

摘要

Abstract

Objective. Based on our preliminary research, our team further assessed the application value of PPIH in the early diagnosis and prognosis monitoring of hepatocellular carcinoma (HCC), establishing a solid foundation for elucidating the primary molecular mechanisms of PPIH in the onset and progression of HCC. We utilized bioinformatics analysis combined with clinical sample evaluation to study PPIH’s mRNA and protein expression and its gene regulation networks in HCC. Additionally, we used data from the TCGA database to examine the relationship between PPIH expression and HCC patient age, gender, and TP53 gene mutation status. The mRNA expression level of PPIH in HCC patients was higher than that in adjacent normal tissues, and Western Blot analysis preliminarily confirmed that PPIH expression was also elevated in HCC tissues compared to matched adjacent normal tissues. However, compared to the normal human liver cell line (L-02), the expression of PPIH in liver cancer cell lines (SMCC7721, HepG2, HepG2.2.15, and MHCC97H) showed no significant differences. Furthermore, the PPIH gene is associated with the regulation of non-coding RNA. It was also found that PPIH expression is positively correlated with the TP53 mutation burden in HCC. However, regardless of the TP53 gene mutation status in HCC, there is no correlation between PPIH expression levels and the gender or age of HCC patients. PPIH holds significant reference value for the diagnosis and prognosis monitoring of HCC and shows potential for clinical application.